Related Experiment Videos

Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients

C H Saely1, L Koch, F Schmid

  • 1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, Austria.

European Journal of Clinical Investigation
|January 27, 2006
PubMed

Insights

Lipoprotein(a) [Lp(a)] is a cardiovascular risk factor, but its association with vascular events differs in diabetic patients. In coronary patients with type 2 diabetes, Lp(a) levels are lower and do not predict vascular events.

Area of Science:

  • Cardiology
  • Endocrinology
  • Clinical Risk Assessment

Background:

  • Lipoprotein(a) [Lp(a)] is a recognized cardiovascular risk factor.
  • Data on Lp(a) and vascular risk in diabetes patients are limited and conflicting.
  • The impact of diabetes on Lp(a) and vascular events in coronary patients remains unclear.

Purpose of the Study:

  • To investigate the association between Lp(a) levels and vascular events in patients with coronary artery disease.
  • To determine if type 2 diabetes mellitus modifies the predictive value of Lp(a) for vascular events.

Main Methods:

  • Measured Lp(a) in 587 patients undergoing coronary angiography.
  • Followed patients for 4 years to record vascular events.
  • Analyzed Lp(a) association with vascular events, considering diabetes status.

Main Results:

  • Lp(a) levels were lower in patients with type 2 diabetes (T2DM) compared to non-diabetic individuals.
  • Lp(a) independently predicted vascular events in non-diabetic patients but not in T2DM patients.
  • A significant interaction between diabetes and Lp(a) indicated Lp(a) is a weaker predictor in T2DM.

Conclusions:

  • In diabetic coronary patients, Lp(a) is low and not linked to vascular events.
  • Lp(a) measurement is valuable for risk assessment in non-diabetic coronary patients.
  • Lp(a) offers limited prognostic value in coronary patients with T2DM.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...